Genetic Analysis AS develops in-vitro diagnostics tests in diseases where microbiota is involved. It is a molecular diagnostic company that provides gut microbiota analysis for testing bacterial imbalance in bowel syndrome and inflammatory bowel disease patients. The company's service products include GA-map dysbiosis test and COVID-19 fecal test and lab products include The GA-map dysbiosis test reagent kit and The COVID fecal test reagent kit. Genetic Analysis was founded in 2008 and is headquartered in Oslo, Norway.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company